Ordering
Available Variants10 mg
CHA.24207-10mg
Price
€168.00
Available – Dispatch in 14 days
50 mg
CHA.24207-50mg
Price
€675.20
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
10 mg | CHA.24207-10mg | €168.00 |
|
Available – Dispatch in 14 days
Global Network - International delivery
|
50 mg | CHA.24207-50mg | €675.20 |
≥98% (HPLC)
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C26H21N3O |
|---|---|
| CAS Number | 105431-72-9 |
| Molecular Weight | 391.46 |
| NACRES | NA.22 |
| PubChem Substance ID | 57654323 |
| UNSPSC Code | 12352100 |
| MDL number | MFCD00867216 |
| Assay | ≥98% (HPLC) |
Safety Information Handling visibility
| Storage Class | 11 - Combustible Solids |
|---|---|
| wgk | WGK 3 |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
| ppe | Eyeshields, Gloves, type N95 (US) |
Technical Overview & Applications Use-case context
Linopirdine, with a CAS number of 105431-72-9, is a potent and selective M1 muscarinic receptor antagonist. It has been investigated for its potential therapeutic applications, particularly in the treatment of cognitive disorders such as Alzheimers disease. The compound exhibits high affinity for M1 receptors, which are implicated in various neurological processes, including memory and learning. Linopirdines mechanism of action involves blocking the action of acetylcholine at M1 receptors, thereby modulating cholinergic neurotransmission. This antagonism is thought to contribute to its potential cognitive-enhancing effects. Although linopirdine has shown promise in preclinical studies, its development as a therapeutic agent has been hindered by concerns regarding its safety and efficacy in human subjects, highlighting the need for further research to fully elucidate its pharmacological properties and potential clinical utility.
